CYP2C19 Genetic Variants Affect Nelfinavir Pharmacokinetics and Virologic Response in HIV-1–Infected Children Receiving Highly Active Antiretroviral Therapy.

Authors :: Saitoh, Akihiko
Capparelli, Edmund
Aweeka, Francesca
Sarles, Elizabeth
Singh, Kumud K.
Kovacs, Andrea
Burchett, Sandra K.
Wiznia, Andrew
Nachman, Sharon
Fenton, Terence
Spector, Stephen A.
Source :: JAIDS: Journal of Acquired Immune Deficiency Syndromes. 7/1/2010, Vol. 54 Issue 3, p285-289. 5p. 1 Diagram, 1 Chart.
Publication Year :: 2010
Abstract: The article presents a study which examines the effect of P-glycoprotein (ABCB1) genetic variants and cytochrome P450 (CYP) on nelfinavir pharmacokinetics and virologic response to highly active antiretroviral therapy (HAART) in HIV-1-infected children. Researchers perform genomic DNA assay among HIV-1-infected children using real-time polymerase chain reaction (PCR). Results show that nelfinavir pharmacokinetics and response to HAART in children are changed by CYP2C19 genotypes.

Subjects :: *P-glycoprotein
*CYTOCHROME P-450
*PHARMACOKINETICS
*HIV-positive children
*HIGHLY active antiretroviral therapy
*IMMUNE response
*POLYMERASE chain reaction

Full Text Access

Tools